GlassScriptPhysician profile
Alda Taube
NPI 1275092629
$1,279.85
in general payments reported to CMS, 2019-2025
18 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $56.74 · 2023: $480 · 2024: $208 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $214.53 | 2023-2025 | Livmarli |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2023 | Bylvay |
| Takeda Pharmaceuticals U.S.A., INC. | $135.34 | 2024-2025 | Eohilia, Gattex |
| Fresenius Kabi USA, LLC | $121.61 | 2023 | Smoflipid |
| Qol Medical, LLC | $90.59 | 2024-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $84.18 | 2023 | Linzess |
| Merck Sharp & Dohme LLC | $67.50 | 2022-2023 | Vaxelis, Gardasil 9, Vaxneuvance |
| Abbvie INC. | $55.13 | 2021 | |
| Alcresta Therapeutics, INC. | $54.96 | 2023-2025 | Relizorb |
| Nestle Healthcare Nutrition INC. | $54.42 | 2021-2023 | |
| Albireo Pharma, INC. | $49.63 | 2024 | Bylvay |
| Rhythm Pharmaceuticals, INC. | $48.22 | 2025 | Imcivree |
| Neurocrine Biosciences, INC. | $35.64 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $25.31 | 2023 | Dupixent |
| Ascendis Pharma Endocrinology INC | $24.72 | 2025 | Skytrofa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyera Pharmaceuticals, LLC | $24.32 | 2021 | |
| Celltrion USA INC. | $22.74 | 2024 | Zymfentra |
| Lilly USA, LLC | $21.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alda Taube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.